{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T12:21:21Z","timestamp":1788092481209,"version":"build-2803163510"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Epilepsy is a common neurologic disease that requires treatment with one or more medications. Due to the polypharmaceutical treatments, potential side effects, and drug-drug interactions associated with these medications, therapeutic drug monitoring is important. Therapeutic drug monitoring is typically performed in blood due to established clinical ranges. While blood provides the benefit of determining clinical ranges, urine requires a less invasive collection method, which is attractive for medication monitoring. As urine does not typically have established clinical ranges, it has not become a preferred specimen for monitoring medication adherence. Thus, large urine clinical data sets are rarely published, making method development that addresses reasonable concentration ranges difficult. An initial method developed and validated in-house utilized a universal analytical range of 50\u20135,000 ng\/mL for all antiepileptic drugs and metabolites of interest in this work, namely carbamazepine, carbamazepine-10,11-epoxide, eslicarbazepine, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, 4-hydroxyphenytoin, and topiramate. This upper limit of the analytical range was too low leading to a repeat rate of 11.59% due to concentrations &amp;gt;5,000 ng\/mL. Therefore, a new, fast liquid chromatography\u2013tandem mass spectrometry (LC\u2013MS-MS) method with a run time under 4 minutes was developed and validated for the simultaneous quantification of the previously mentioned nine antiepileptic drugs and their metabolites. Urine samples were prepared by solid-phase extraction and analyzed using a Phenomenex Phenyl-Hexyl column with an Agilent 6460 LC\u2013MS-MS instrument system. During method development and validation, the analytical range was optimized for each drug to reduce repeat analysis due to concentrations above the linear range and for carryover. This reduced the average daily repeat rate for antiepileptic testing from 11.59% to 4.82%. After validation, this method was used to test and analyze patient specimens over the course of approximately one year. The resulting concentration data were curated to eliminate specimens that could indicate an individual was noncompliant with their therapy (i.e., positive for illicit drugs) and yielded between 20 and 1,700 concentration points from the patient specimens, depending on the analyte. The resulting raw quantitative urine data set is presented as preliminary reference ranges to assist with interpreting urine drug concentrations for the nine aforementioned antiepileptic medications and metabolites.<\/jats:p>","DOI":"10.1093\/jat\/bkaa095","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T07:08:50Z","timestamp":1595660930000},"page":"688-696","source":"Crossref","is-referenced-by-count":11,"title":["A Rapid LC\u2013MS-MS Method for the Quantitation of Antiepileptic Drugs in Urine"],"prefix":"10.1093","volume":"44","author":[{"given":"Sheng","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Toxicology, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandi","family":"Bridgewater","sequence":"additional","affiliation":[{"name":"Research and Development Department, Ameritox LLC, 486 Gallimore Dairy Rd, Greensboro, NC 27409, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin C","family":"Strickland","sequence":"additional","affiliation":[{"name":"Research and Development Department, Ameritox LLC, 486 Gallimore Dairy Rd, Greensboro, NC 27409, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"McIntire","sequence":"additional","affiliation":[{"name":"Research and Development Department, Premier Biotech, 723 Kasota Ave SE, Minneapolis, MN 55414, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"key":"2020101206543814600_R0001","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1212\/01.wnl.0000252807.38124.a3","article-title":"How common are the \u201ccommon\u201d neurologic disorders?","volume":"68","author":"Hirtz,","year":"2007","journal-title":"Neurology"},{"key":"2020101206543814600_R0002","doi-asserted-by":"publisher","first-page":"821","DOI":"10.15585\/mmwr.mm6631a1","article-title":"National and state estimates of the numbers of adults and children with active epilepsy\u2014United States, 2015","volume":"66","author":"Zack,","year":"2017","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"2020101206543814600_R0003","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/j.1528-1167.2009.02481.x","article-title":"Estimation of the burden of active and life-time epilepsy: a meta-analytic approach","volume":"51","author":"Ngugi,","year":"2010","journal-title":"Epilepsia"},{"key":"2020101206543814600_R0004","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.pharep.2014.11.009","article-title":"Antiepileptic drugs and adverse skin reactions: an update","volume":"67","author":"Blaszczyk,","year":"2015","journal-title":"Pharmacological Reports"},{"key":"2020101206543814600_R0005","first-page":"563","article-title":"Epilepsy, antiepileptic drugs, and aggression: an evidence-based review","volume":"68","author":"Brodie,","year":"2016","journal-title":"Pharmacological Reports"},{"key":"2020101206543814600_R0006","first-page":"223","article-title":"Abuse potential of carbamazepine for euphorigenic effects","volume":"65","author":"Hosseini,","year":"2015","journal-title":"Drug Research (Stuttgart)"},{"key":"2020101206543814600_R0007","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.yebeh.2017.10.007","article-title":"When adverse effects are seen as desirable: abuse potential of the newer generation antiepileptic drugs","volume":"77","author":"Hawkins,","year":"2017","journal-title":"Epilepsy & Behavior"},{"key":"2020101206543814600_R0008","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jchromb.2009.11.039","article-title":"Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy","volume":"878","author":"Contin,","year":"2010","journal-title":"Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences"},{"key":"2020101206543814600_R0009","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/chromsci\/45.9.616","article-title":"Drug monitoring: simultaneous analysis of lamotrigine, oxcarbazepine, 10-hydroxycarbazepine, and zonisamide by HPLC-UV and a rapid GC method using a nitrogen-phosphorus detector for levetiracetam","volume":"45","author":"Greiner-Sosanko,","year":"2007","journal-title":"Journal of Chromatographic Science"},{"key":"2020101206543814600_R0010","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/S0731-7085(03)00525-9","article-title":"Simultaneous separation and quantitation of four antiepileptic drugs\u2014a study with potential for use in patient drug level monitoring","volume":"34","author":"Manoj Babu,","year":"2004","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"2020101206543814600_R0011","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/00007691-200008000-00016","article-title":"Comparison of topiramate concentrations in plasma and serum by fluorescence polarization immunoassay","volume":"22","author":"Berry,","year":"2000","journal-title":"Therapuetic Drug Monitoring"},{"key":"2020101206543814600_R0012","first-page":"87","article-title":"Restricted-access media high pressure liquid chromatography vs fluorescence polarization immunoassay for analysis of carbamazepine in human plasma","volume":"23","author":"Ma,","year":"2002","journal-title":"Acta Pharmacologica Sinica B"},{"key":"2020101206543814600_R0013","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0009-9120(82)96854-0","article-title":"Comparison of fluorescent immunoassay (FIA) and enzyme-multiplied immunoassay technique (emit) for measurement of serum carbamazepine concentration","volume":"15","author":"Carl,","year":"1982","journal-title":"Clinical Biochemistry"},{"key":"2020101206543814600_R0014","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jpba.2011.07.019","article-title":"Simple and accurate quantitative analysis of ten antiepileptic drugs in human plasma by liquid chromatography\/tandem mass spectrometry","volume":"56","author":"Kim,","year":"2011","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"issue":"12","key":"2020101206543814600_R0015","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/bmc.2726","article-title":"Detection of 22 antiepileptic drugs by ultra-performance liquid chromatography coupled with tandem mass spectrometry applicable to routine therapeutic drug monitoring","volume":"26","author":"Shibata,","year":"2012","journal-title":"Biomedical Chromatography"},{"key":"2020101206543814600_R0016","volume-title":"Disposition of Toxic Drugs and Chemicals in Man","author":"Baselt,","year":"2017","edition":"11th edition"},{"key":"2020101206543814600_R0017","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/FTD.0b013e3181678ecb","article-title":"High-speed simultaneous determination of nine antiepileptic drugs using liquid chromatography-mass spectrometry","volume":"30","author":"Subramanian,","year":"2008","journal-title":"Therapeutic Drug Monitoring"},{"key":"2020101206543814600_R0018","volume-title":"Manual for Urine Laboratories","author":"National Laboratory Certification Program (NLCP)","year":"2010"},{"key":"2020101206543814600_R0019","volume-title":"Guidance for Industry-Bioanalytical Method Validation","author":"U.S. Department of Health and Human Services, Food and Drug Administration","year":"2001"},{"key":"2020101206543814600_R0020","volume-title":"CLIA-Compliant Analytical Method Validation Plan and Template for LRN-C Laboratories","author":"Association of Public Health Laboratories","year":"2013"},{"key":"2020101206543814600_R0021","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.forsciint.2006.05.021","article-title":"Validation of new methods","volume":"165","author":"Peters,","year":"2007","journal-title":"Forensic Science International"},{"key":"2020101206543814600_R0022","first-page":"114","volume-title":"Principles of Forensic Toxicology","author":"Levine,","year":"2003","edition":"2nd edition"},{"key":"2020101206543814600_R0023","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1093\/jat\/bkv087","article-title":"A dilute-and-shoot LC-MS method for quantitating opioids in oral fluid","volume":"39","author":"Enders,","year":"2015","journal-title":"Journal of Analytical Toxicology"},{"key":"2020101206543814600_R0024","article-title":"UCB, Inc. (per FDA): Smyrna, GA,","volume-title":"Inc. Product Information: KEPPRA(R) (levetiracetam) tablets and oral solution.","author":"UCB","year":"2009"},{"key":"2020101206543814600_R0025","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1309\/AJCPFAHVB26VVVTE","article-title":"Estimation of carbamazepine and carbamazepine-10,11-epoxide concentrations in plasma using mathematical equations generated with two carbamazepine immunoassays","volume":"133","author":"McMillin,","year":"2010","journal-title":"American Journal of Clinical Pathology"},{"key":"2020101206543814600_R0026","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0021-9673(01)94635-7","article-title":"Simultaneous determination of zonisamide and nine other anti-epileptic drugs and metabolites in serum. A comparison of microbore and conventional high-performance liquid chromatography","volume":"385","author":"Juergens,","year":"1987","journal-title":"Journal of Chromatography A"},{"key":"2020101206543814600_R0027","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/jat\/bks018","article-title":"Evaluating the relationship between carisoprodol concentrations and meprobamate formation and inter-subject and intra-subject variability in urinary excretion data of pain patients","volume":"36","author":"Tse,","year":"2012","journal-title":"Journal of Analytical Toxicology"},{"key":"2020101206543814600_R0028","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/jat\/bks022","article-title":"Observations on the urine metabolic ratio of oxymorphone to oxycodone in pain patients","volume":"36","author":"Yee,","year":"2012","journal-title":"Journal of Analytical Toxicology"},{"key":"2020101206543814600_R0029","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/jat\/bks020","article-title":"Evaluating the relationship of methadone concentrations and EDDP formation in chronic pain patients","volume":"36","author":"Leimanis,","year":"2012","journal-title":"Journal of Analytical Toxicology"},{"key":"2020101206543814600_R0030","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/jat\/bks021","article-title":"Observations on the metabolism of morphine to hydromorphone in pain patients","volume":"36","author":"Hughes,","year":"2012","journal-title":"Journal of Analytical Toxicology"},{"key":"2020101206543814600_R0031","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/jat\/bks019","article-title":"Relationship between the concentration of hydrocodone and its conversion to hydromorphone in chronic pain patients using urinary excretion data","volume":"36","author":"Barakat,","year":"2012","journal-title":"Journal of Analytical Toxicology"},{"key":"2020101206543814600_R0032","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1093\/jat\/bkw057","article-title":"Normalizing oral fluid hydrocodone data using calculated blood volume","volume":"40","author":"Cummings,","year":"2016","journal-title":"Journal of Analytical Toxicology"},{"key":"2020101206543814600_R0033","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/jat\/bkw067","article-title":"Fentanyl-norfentanyl concentrations during transdermal patch application: LC-MS-MS urine analysis","volume":"40","author":"Cummings,","year":"2016","journal-title":"Journal of Analytical Toxicology"},{"key":"2020101206543814600_R0034","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jat\/33.1.1","article-title":"Normalization of urinary drug concentrations with specific gravity and creatinine","volume":"33","author":"Cone,","year":"2009","journal-title":"Journal of Analytical Toxicology"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkaa095\/33559198\/bkaa095.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jat\/article-pdf\/44\/7\/688\/33863600\/bkaa095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jat\/article-pdf\/44\/7\/688\/33863600\/bkaa095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T06:55:17Z","timestamp":1602485717000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/44\/7\/688\/5879805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,8,3]]},"published-print":{"date-parts":[[2020,10,12]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkaa095","relation":{},"ISSN":["0146-4760","1945-2403"],"issn-type":[{"value":"0146-4760","type":"print"},{"value":"1945-2403","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,8,3]]}}}